Systemic Juvenile Idiopathic Arthritis Market Report 2026

The systemic juvenile idiopathic arthritis market size has grown strongly in recent years. It will grow from $1.36 billion in 2025 to $1.44 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to improved recognition of sjia as a distinct condition, increasing availability of biologic drugs, expansion of pediatric specialty care, growth of academic research programs, improved diagnostic criteria for inflammatory diseases.

The systemic juvenile idiopathic arthritis market size is expected to see strong growth in the next few years. It will grow to $1.8 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing investments in pediatric autoimmune research, rising adoption of interleukin-targeted therapies, expansion of clinical trials for rare diseases, growing focus on personalized medicine, increasing access to specialty pediatric care. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising focus on early and accurate sjia diagnosis, growing use of personalized treatment protocols, expansion of clinical research in pediatric rheumatology, enhanced monitoring of disease progression.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the systemic juvenile idiopathic arthritis market. Autoimmune disorders occur when the body’s immune system mistakenly attacks its own healthy cells, tissues, or organs. The rise in these disorders is largely attributed to genetic susceptibility, as inherited genes can predispose individuals to abnormal immune responses that target the body’s own tissues. Systemic juvenile idiopathic arthritis (SJIA) represents a distinct autoimmune condition that provides insights into the mechanisms of immune dysregulation and inflammatory pathways underlying disease progression. Studying SJIA allows researchers to better understand how abnormal immune responses contribute to widespread inflammation and tissue damage characteristic of autoimmune diseases. For example, in February 2024, Arthritis Australia, a non-profit organization, reported that an estimated 212,136 males and 362,137 females were projected to have rheumatoid arthritis (RA), with numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the rising prevalence of autoimmune disorders is driving the SJIA market.

Companies operating in the systemic juvenile idiopathic arthritis market are focusing on innovative products, such as intravenous formulations, to improve efficacy, safety, and patient compliance. Intravenous formulations are drugs administered directly into the bloodstream, enabling rapid and controlled therapeutic effects. For instance, in October 2025, Celltrion Inc., a South Korea-based biopharmaceutical company, launched AVTOZMA, a tocilizumab biosimilar intravenous formulation, in the United States. This biosimilar serves as an alternative to the reference product Actemra and has been approved for multiple indications, including SJIA, rheumatoid arthritis, and cytokine release syndrome. AVTOZMA is expected to enhance patient access to advanced therapies by offering a cost-effective treatment option while maintaining comparable safety, efficacy, and quality standards to the original drug. By providing both intravenous and subcutaneous formulations, AVTOZMA gives clinicians greater flexibility in tailoring treatment regimens to individual patient needs, optimizing therapeutic outcomes across clinical settings.

In April 2025, Organon & Co., a US-based pharmaceutical company, acquired Tofidence (tocilizumab-bavi), a biosimilar to Actemra injection, from Biogen for an undisclosed amount. This acquisition was aimed at strengthening and expanding Organon’s U.S. immunology and biosimilars portfolio by adding a multi-indication arthritis treatment. Biogen Inc., a US-based biotechnology company, provides treatments for systemic juvenile idiopathic arthritis.

Major companies operating in the systemic juvenile idiopathic arthritis market are Johnson And Johnson, F. Hoffmann-La Roche Limited, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly And Company, Takeda Pharmaceutical Company Limited, Amgen Incorporated, Boehringer Ingelheim, Regeneron Pharmaceuticals Incorporated, Chugai Pharmaceutical Company Limited, Genentech Incorporated, Swedish Orphan Biovitrum Aktiebolag, Zydus Lifesciences Limited, Celltrion Incorporated, Mycenax Biotech Incorporated.

North America was the largest region in the systemic juvenile idiopathic arthritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic juvenile idiopathic arthritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the systemic juvenile idiopathic arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the systemic juvenile idiopathic arthritis market by increasing costs of imported biologic drugs, active pharmaceutical ingredients, diagnostic reagents, and specialized medical devices used in treatment and monitoring. Healthcare systems in North America and Europe are most affected due to reliance on imported biologics, while Asia-Pacific faces higher costs for advanced therapies. These tariffs are contributing to increased treatment expenses and reimbursement pressures. However, they are also encouraging domestic biologics manufacturing, regional clinical research investment, and improved supply chain localization for pediatric therapeutics.

The systemic juvenile idiopathic arthritis market research report is one of a series of new reports that provides systemic juvenile idiopathic arthritis market statistics, including systemic juvenile idiopathic arthritis industry global market size, regional shares, competitors with a systemic juvenile idiopathic arthritis market share, detailed systemic juvenile idiopathic arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the systemic juvenile idiopathic arthritis industry. This systemic juvenile idiopathic arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Systemic juvenile idiopathic arthritis (SJIA) is a rare form of childhood arthritis that causes inflammation throughout the body, not just in the joints. It is characterized by persistent high fevers, rashes, and swelling or pain in multiple joints. Unlike other types of juvenile arthritis, SJIA can also affect internal organs such as the liver, spleen, and heart. The exact cause is unknown, but it is thought to involve an abnormal immune system response.

The main treatment types for systemic juvenile idiopathic arthritis include drug treatments, biologics, and other therapies. Drug treatments involve medications such as biologics, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) to reduce inflammation, manage symptoms, and prevent joint damage in patients with SJIA. These treatments are used across various age groups, including infants, children, and adolescents. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by hospitals, specialty clinics, academic research centers, and other healthcare providers.

The systemic juvenile idiopathic arthritis market consists of revenues earned by entities by providing services such as pharmaceutical treatments, clinical consultation services, hospital and outpatient care, diagnostic services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The systemic juvenile idiopathic arthritis market also includes sales of canakinumab, tocilizumab, methotrexate, corticosteroids, and nonsteroidal anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.